Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2018 Oct 12

PMID 30307776

Citations 81

Authors

Scott C Morgan

Karen Hoffman

D Andrew Loblaw

Mark K Buyyounouski

Caroline Patton

Daniel Barocas

Soren Bentzen

Michael Chang

Jason Efstathiou

Patrick Greany

Per Halvorsen

Bridget F Koontz

Colleen Lawton

C Marc Leyrer

Daniel Lin

Michael Ray

Howard Sandler

Affiliations

Soon will be listed here.

Citing Articles

A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer.

Okonogi N, Tsuji H, Kobayashi K, Nakajima M, Aoki S, Utsumi T Adv Radiat Oncol. 2025; 10(3):101705.

PMID: 39991117 PMC: 11847242. DOI: 10.1016/j.adro.2024.101705.

Moderate Hypofractionated Post-Prostatectomy Radiotherapy (MYSTERY) Versus Conventionally Fractionated Post-Prostatectomy Radiotherapy (COPORT) for the Patients With Localized Prostate Cancer: The Protocol of a Prospective, Randomized Trial.

Liang Y, Zhang W, Zhao X, Zhang H Cancer Control. 2025; 32:10732748251317682.

PMID: 39933701 PMC: 11815805. DOI: 10.1177/10732748251317682.

The status quo of global geriatric radiation oncology education: A scoping review.

Morris L, Turner S, Phillips J, Parmar A, Agar M Tech Innov Patient Support Radiat Oncol. 2024; 32:100288.

PMID: 39629008 PMC: 11613160. DOI: 10.1016/j.tipsro.2024.100288.

Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 3. Genitourinary and gynecological cancers.

Yoo G, Sung S, Song J, Kim B, Kwak Y, Kim K Radiat Oncol J. 2024; 42(3):171-180.

PMID: 39354820 PMC: 11467485. DOI: 10.3857/roj.2023.01046.

Automated plan generation for prostate radiotherapy patients using deep learning and scripted optimization.

Church C, Yap M, Bessrour M, Lamey M, Granville D Phys Imaging Radiat Oncol. 2024; 32:100641.

PMID: 39310221 PMC: 11415801. DOI: 10.1016/j.phro.2024.100641.

References

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D . Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17(8):1047-1060. PMC: 4961874. DOI: 10.1016/S1470-2045(16)30102-4. View

Hannan R, Tumati V, Xie X, Cho L, Kavanagh B, Brindle J . Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016; 59:142-151. DOI: 10.1016/j.ejca.2016.02.014. View

Pollack A, Walker G, Horwitz E, Price R, Feigenberg S, Konski A . Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013; 31(31):3860-8. PMC: 3805927. DOI: 10.1200/JCO.2013.51.1972. View

Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari M, Sanguineti G . Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. J Clin Oncol. 2017; 35(17):1891-1897. DOI: 10.1200/JCO.2016.70.4189. View

Ghilezan M, Jaffray D, Siewerdsen J, Van Herk M, Shetty A, Sharpe M . Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005; 62(2):406-17. DOI: 10.1016/j.ijrobp.2003.10.017. View

Teh B, Mai W, Uhl B, Augspurger M, Grant 3rd W, Lu H . Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys. 2001; 49(3):705-12. DOI: 10.1016/s0360-3016(00)01428-0. View

King C, Brooks J, Gill H, Pawlicki T, Cotrutz C, Presti Jr J . Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2008; 73(4):1043-8. DOI: 10.1016/j.ijrobp.2008.05.059. View

Catton C, Lukka H, Gu C, Martin J, Supiot S, Chung P . Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017; 35(17):1884-1890. DOI: 10.1200/JCO.2016.71.7397. View

Loblaw A, Cheung P, DAlimonte L, Deabreu A, Mamedov A, Zhang L . Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013; 107(2):153-8. DOI: 10.1016/j.radonc.2013.03.022. View

10.

Rucinska M, Kieszkowska-Grudny A, Nawrocki S . SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment. Strahlenther Onkol. 2016; 192(7):449-57. PMC: 4919372. DOI: 10.1007/s00066-016-0971-2. View

11.

Incrocci L, Wortel R, Alemayehu W, Aluwini S, Schimmel E, Krol S . Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016; 17(8):1061-1069. DOI: 10.1016/S1470-2045(16)30070-5. View

12.

Zelefsky M, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X . Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1):125-9. DOI: 10.1016/j.ijrobp.2011.11.047. View

13.

Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M . A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol. 2013; 8:206. PMC: 3846611. DOI: 10.1186/1748-717X-8-206. View

14.

Miralbell R, Roberts S, Zubizarreta E, Hendry J . Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2011; 82(1):e17-24. DOI: 10.1016/j.ijrobp.2010.10.075. View

15.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C . Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015; 16(16):1605-16. PMC: 4664817. DOI: 10.1016/S1470-2045(15)00280-6. View

16.

Bolzicco G, Silvia Favretto M, Satariano N, Scremin E, Tambone C, Tasca A . A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 2013; 13:49. PMC: 4016542. DOI: 10.1186/1471-2490-13-49. View

17.

Sandler H, Liu P, Dunn R, Khan D, Tropper S, Sanda M . Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010; 75(5):1004-8. PMC: 6089222. DOI: 10.1016/j.urology.2009.10.072. View

18.

Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn P, Jager H . Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016; 17(4):464-474. DOI: 10.1016/S1470-2045(15)00567-7. View

19.

Chen L, Suy S, Uhm S, Oermann E, Ju A, Chen V . Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013; 8:58. PMC: 3610192. DOI: 10.1186/1748-717X-8-58. View

20.

ODoherty U, McNair H, Norman A, Miles E, Hooper S, Davies M . Variability of bladder filling in patients receiving radical radiotherapy to the prostate. Radiother Oncol. 2006; 79(3):335-40. DOI: 10.1016/j.radonc.2006.05.007. View